Romosozumab API is a recombinant humanized monoclonal antibody and a targeted pharmaceutical biologic used in the treatment of osteoporosis. Romosozumab is a humanized IgG2 monoclonal antibody directed against sclerostin, a regulatory protein involved in bone metabolism.
Romosozumab works by inhibiting sclerostin activity, resulting in increased bone formation and, to a lesser extent, decreased bone resorption. The active substance is used in the development and manufacture of pharmaceutical products for patients with severe osteoporosis and high fracture risk.
Romosozumab is a recombinant humanized monoclonal antibody produced using a mammalian cell-expression system. FDA identifies the product as romosozumab-aqqg, produced in a Chinese Hamster Ovary (CHO) cell line using recombinant DNA technology. The antibody has an approximate molecular weight of 149 kDa.
FDA GSRS identifies CAS 909395-70-6 and UNII 3VHF2ZD92J for romosozumab.
Unlike conventional small-molecule APIs, Romosozumab is a complex biological macromolecule consisting of heavy and light immunoglobulin chains linked by disulfide bonds and containing N-linked glycans.
FDA's regulatory assessment reports a theoretical mass of approximately 145,622 Da for the fully assembled, disulfide-bonded antibody without N-linked glycans, while the marketed antibody has an approximate molecular weight of 149 kDa after consideration of its glycosylation profile.
Because Romosozumab is a biological API, quality characterization requires assessment of molecular identity, purity, aggregation, charge variants, glycosylation, biological activity and other critical quality attributes rather than conventional small-molecule tests such as chemical assay by simple HPLC alone.
Romosozumab is used as an active biological ingredient for pharmaceutical treatment of osteoporosis.
The EMA indicates that Evenity (romosozumab) is used for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. The recommended regimen is 210 mg administered subcutaneously once monthly for 12 months.
The pharmaceutical substance is therefore relevant to:
Romosozumab binds to and inhibits sclerostin, a protein that negatively regulates bone formation.
By inhibiting sclerostin, Romosozumab promotes Wnt signaling and stimulates osteoblastic activity, resulting in increased bone formation. It also produces a lesser reduction in bone resorption. This dual effect contributes to increased trabecular and cortical bone mass and improved bone structure and strength.
Quality control of Romosozumab requires a comprehensive biologics analytical characterization program.
Important quality attributes include:
Analytical techniques for monoclonal antibodies may include chromatographic, electrophoretic, spectrometric and biological activity assays. Because Romosozumab is a recombinant monoclonal antibody, its specifications should be based on the validated biological-product control strategy rather than conventional small-molecule API specifications.
Romosozumab is manufactured using recombinant biotechnology in a mammalian cell-expression system. FDA identifies the manufacturing cell system as Chinese Hamster Ovary (CHO) cells.
Manufacturing of this type of biological API requires controlled cell culture, harvesting, purification and viral-safety controls, followed by formulation and extensive characterization of the purified antibody.
Critical manufacturing controls are necessary to maintain antibody identity, structural integrity, glycosylation characteristics, purity and biological activity.
Romosozumab is a recombinant humanized IgG2 monoclonal antibody rather than a conventional low-molecular-weight chemical compound.
Key properties include:
Romosozumab biological material requires controlled cold-chain handling.
The EMA product information states that the finished product should be stored refrigerated at 2–8°C, should not be frozen, and should be protected from light by keeping the syringe in its outer carton.
The EMA assessment report supports a 3-year finished-product shelf life when stored at 2–8°C, with an optional short-term storage period at room temperature of no more than 30 days under the specified conditions.
A qualified Romosozumab biological API manufacturer can provide applicable quality and regulatory documentation, including:
A qualified Romosozumab API manufacturer in India can support pharmaceutical biotechnology companies requiring high-quality recombinant monoclonal antibody material.
Romosozumab requires specialized biological manufacturing and characterization capabilities because its quality cannot be adequately defined through conventional small-molecule API testing alone.
Important manufacturing considerations include controlled CHO-cell production, purification, viral safety, protein characterization, glycosylation control, aggregation monitoring, biological activity and cold-chain management.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| pH (1% Solution) | 5.2 |